Navigation Links
Crucell Announces New Award of $110 Million for Paediatric Vaccine Quinvaxem(R) by UNICEF to Support Vaccination Programs in the Developing World
Date:5/6/2010

LEIDEN, The Netherlands, May 6, 2010 /PRNewswire-FirstCall/ -- Dutch biopharmaceutical company Crucell N.V. (NYSE Euronext, NASDAQ: CRXL; Swiss Exchange: CRX) today announced the award from UNICEF of an additional $110 million to supply its paediatric vaccine Quinvaxem(R) to the developing world. Paediatric vaccination plays an important role in contributing to achieving the Millennium Development Goals set by the United Nations, in particular the target of reducing under-five mortality rate by two-thirds between 1990 and 2015. "We are proud to be able to deliver significant amount of additional vaccine orders at short notice," said Ronald Brus, Crucell's Chief Executive Officer. "The capacity and reliability of Crucell's manufacturing and logistical systems allows us to deliver high quality and safe vaccines to protect young children from life threatening diseases in the world's developing countries. As a responsible and reliable partner, we thus contribute to the success of the Global Alliance for Vaccines and Immunisation (GAVI Alliance) in accelerating access to these vaccines across the globe."

From 2006-2009 as part of the Extended Program for Immunization, over 130 million doses of Quinvaxem(R) have been delivered to more than 50 countries. Crucell has been increasing its production capacity over the last few years in order to meet the growing demand for paediatric vaccines from the developing world.

Quinvaxem(R) is the only fully liquid pentavalent DTwP-HepB-Hib vaccine that is free from the preservative thiomersal. It is an optimal solution for protection against five potentially deadly childhood diseases: diphtheria, tetanus, pertussis, Haemoplilus influenza type b infection and hepatitis B. Quinvaxem(R) is ready for use without further preparation steps by healthcare workers in the field, which offers major healthcare advantages for these countries with a challenging infrastructure and hygiene problems.

This latest order brings the overall value of tenders awarded to Crucell for the period of 2010-2012 to $410 million. This is in addition to the $500 million obtained over the tender period 2007-2009. They bring the total value of contracts awarded since the launch of Quinvaxem(R) at the end of 2006 to $910 million. During the first tender round in 2006, Crucell was initially awarded $230 million (December 2006) and received additional incremental awards of $130 million and $140 million in May and September 2008, respectively.

Forward-looking statements

This press release contains forward-looking statements that involve inherent risks and uncertainties. We have identified certain important factors that may cause actual results to differ materially from those contained in such forward-looking statements. For information relating to these factors please refer to our Form 20-F, as filed with the US Securities and Exchange Commission on April 7, 2010, in the section entitled 'Risk Factors'. The Company prepares its financial statements under International Financial Reporting Standards (IFRS).

About Crucell

Crucell N.V. (NYSE Euronext, NASDAQ: CRXL; Swiss Exchange: CRX) is a global biopharmaceutical company focused on research development, production and marketing of vaccines, proteins and antibodies that prevent and/or treat infectious diseases. In 2009 alone, Crucell distributed more than 115 million vaccine doses in more than 100 countries around the world, with the fast majority of doses (97%) going to developing countries. Crucell is one of the major suppliers of vaccines to UNICEF and the developing world. Crucell was the first manufacturer to launch a fully-liquid pentavalent vaccine called Quinvaxem(R). Quinvaxem(R) protects against five important childhood diseases and over 130 million doses have been sold since its launch in 2006 in more than 50 GAVI countries. Through Quinvaxem(R) and its innovation, Crucell has become a major partner in protecting children in developing countries. Crucell's core portfolio also includes a vaccine against hepatitis B and a virosome-adjuvanted vaccine against influenza. Crucell also markets travel vaccines, such as an oral anti-typhoid vaccine, an oral cholera vaccine and the only aluminum-free hepatitis A vaccine on the market. The Company has a broad development pipeline, with several product candidates based on its unique PER.C6(R) production technology. The Company licenses its PER.C6(R) technology and other technologies to the biopharmaceutical industry. Important partners and licensees include Johnson & Johnson, DSM Biologics, sanofi-aventis, Novartis, Wyeth, GSK, CSL and Merck & Co. Crucell is headquartered in Leiden, the Netherlands, with subsidiaries in Argentina, China, Italy, Korea, Spain, Sweden, Switzerland, UK and the USA. The Company employs over 1200 people. For more information, please visit http://www.crucell.com.


'/>"/>
SOURCE Crucell N.V
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. DSM and Crucell Announce Another Key Achievement for PER.C6(R) Technology; Scale Up of High-Titer Fed-Batch Process to 250 Liters
2. DSM Biologics and Crucell Announce Commercial PER.C6(R) Licensing Agreement with Gedeon Richter
3. DSM and Crucell Sign Agreement with Bioceros to Serve as Pre-Approved Cell Line Generation Partner of PER.C6(R) Cell Line Proteins
4. Confirmation of Bogoch Replikins Influenza Patents by Harvard-CDC and Scripps-Crucell Data
5. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
6. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
7. Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering
8. BioLife Solutions Announces Exclusive CryoStor(TM) Supply Agreement With the New England Cryogenic Center, Inc.
9. Carrington Announces Nasdaq Communication; Prepares for Shares to Be Quoted on the OTC Bulletin Board and Pink Sheets
10. China Kangtai Cactus Biotech Files 2nd Quarter 2007 10QSB and Announces Unaudited Quarterly Results
11. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/23/2017)... and NEW YORK ... HIMSS, Lumeon , a leading digital health ... Telehealth), a provider of telemedicine and remote patient ... pathways for telemedicine reimbursements.  DN ... their patients, in real-time, extending consultations beyond a ...
(Date:2/23/2017)... ... February 23, 2017 , ... ... portfolio to include an array of biochemical analyses critical for Lead Discovery. ... drive their hit-to-lead and SAR programs, including inhibitor potency and selectivity, mechanism of ...
(Date:2/23/2017)... Feb. 23, 2017  MIODx announced today that ... key immunotherapy technologies from the University of California, ... method to monitor a patient for response to ... CTLA-4.  The second license extends the technology with ... likely to have an immune-related adverse event (IRAE) ...
(Date:2/23/2017)... 23, 2017  Seattle,s upscale Capitol Hill neighborhood, with its swanky ... for a head lice treatment salon to set up shop. ... restaurant and a French bistro on E Madison Ave, and ... just any old lice clinic, we pride ourselves on being ... release some of the stigma associated with lice. Everyone can ...
Breaking Biology Technology:
(Date:2/8/2017)... 2017 Report Highlights The global ... $8.3 billion in 2016 at a compound annual growth ... Report Includes - An overview of the global market ... data from 2015 and 2016, and projections of compound ... the market on the basis of product type, source, ...
(Date:2/6/2017)... Feb. 6, 2017 According to Acuity ... driving border authorities to continue to embrace biometric ... are 2143 Automated Border Control (ABC) eGates and ... at more than 163 ports of entry across ... 2016 achieving a combined CAGR of 37%. APC ...
(Date:2/2/2017)...  EyeLock LLC, a market leader of iris-based identity ... What You Should Know About Biometrics in the Cloud ... is a growing concern. In traditional schemes, cryptography is ... authentication schemes such as username/password suffer from inherent weaknesses. ... an elegant solution to the problem of high-security user ...
Breaking Biology News(10 mins):